New COPD drug candidate tested for safety in healthy volunteers
NCT ID NCT06908642
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 trial tested the safety of Hemay005 tablets, a potential new drug for chronic obstructive pulmonary disease (COPD), in 468 healthy Chinese adults. Researchers compared different dosing methods (titration vs. non-titration) to see how they affect side effects. The study focused on adverse events, not on treating COPD.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hemay005 (a PDE4 inhibitor drug)
What this could lead to
If successful, this could help determine a safer way to give Hemay005, potentially leading to a new treatment for COPD.
What could go wrong
This is an early Phase 1 safety study in healthy people, not patients. It does not test if the drug works for COPD, and side effects are still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, 241000, China